The abstract is read at the publisher; the summary is JClub's.
Duvakitug 900 mg every 2 weeks produced an endoscopic response in 22 of 46 adults with moderately to severely active Crohn’s disease at week 14, with posterior superiority >0·99 versus placebo.
- Why it matters: The trial addresses the need for effective, well-tolerated treatments for adults with moderately to severely active Crohn’s disease who have inadequate response, loss of response, or intolerance to prior therapies.
- What they did: In a multicentre phase 2b randomized placebo-controlled study, adults aged 18–75 received a 2250 mg loading dose then duvakitug 450 mg or 900 mg every 2 weeks, or placebo, with week-14 endoscopic response assessed using Bayesian posterior probabilities.
- The result: Endoscopic response at week 14 was 12/46 for 450 mg and 6/46 for placebo; adverse events occurred in 67%, 43%, and 48% respectively, with serious adverse events in 13%, 2%, and 11%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.